Unknown

Dataset Information

0

The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer.


ABSTRACT: Although PEGylated filgrastim-induced aortitis is very rare and unknown clinically, some cases were reported and increasing, especially in breast cancer patients. The present study investigated the prevalence, clinical features and treatment of aortitis induced by PEGylated filgrastim in patients with breast cancer. A total of 2068 consecutive patients who underwent neoadjuvant/adjuvant chemotherapy with PEGylated filgrastim for breast cancer were enrolled. From the medical record, clinical, laboratory, medication, and imaging evaluation findings were collected. PEGylated filgrastim-induced aortitis was established in 0.3% of the study population. Common clinical presentations included extremely high fever and chest/back pain with high levels of inflammatory markers without any signs of infection. Contrast-enhanced computed tomography scans revealed typical enhancing wall thickening and periaortic soft tissue infiltration at various levels of aorta. All patients improved rapidly after treatment with modest doses of prednisolone (0.5 mg/kg/day) without any complications. Clinicians should be aware of aortitis as a possible complication of granulocyte-colony stimulating factor therapy, especially PEGylated filgrastim, given the frequent misdiagnoses in neutropenic patients undergoing chemotherapy.

SUBMITTER: Lee SY 

PROVIDER: S-EPMC7596224 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer.

Lee Sang Yoon SY   Kim Eun Kyoung EK   Kim Ji-Yeon JY   Park Taek-Kyu TK   Choi Seung-Hyuk SH   Im Young-Hyuck YH   Kim Min Yeong MY   Park Yeon Hee YH   Kim Duk-Kyung DK  

Scientific reports 20201029 1


Although PEGylated filgrastim-induced aortitis is very rare and unknown clinically, some cases were reported and increasing, especially in breast cancer patients. The present study investigated the prevalence, clinical features and treatment of aortitis induced by PEGylated filgrastim in patients with breast cancer. A total of 2068 consecutive patients who underwent neoadjuvant/adjuvant chemotherapy with PEGylated filgrastim for breast cancer were enrolled. From the medical record, clinical, lab  ...[more]

Similar Datasets

| S-EPMC3883036 | biostudies-literature
| S-EPMC7569697 | biostudies-literature
| S-EPMC5738061 | biostudies-literature
| S-EPMC9830008 | biostudies-literature
| S-EPMC7270760 | biostudies-literature
| S-EPMC3605177 | biostudies-literature
| S-EPMC10457722 | biostudies-literature
| S-EPMC3357629 | biostudies-literature
| S-EPMC7238506 | biostudies-literature
| S-EPMC9307809 | biostudies-literature